Literature DB >> 17229243

Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.

P O Katz1, F K Koch, E D Ballard, R G Bagin, T C Gautille, G C Checani, D L Hogan, V S V Pratha.   

Abstract

BACKGROUND: Gastro-oesophageal reflux disease (GERD) patients on proton pump inhibitors before breakfast or dinner have acid recovery at night. Bedtime immediate-release omeprazole (IR-OME) demonstrated better control of nocturnal pH than pantoprazole before dinner. AIM: To compare repeated once daily bedtime dosing of IR-OME, lansoprazole and esomeprazole on nocturnal gastric acidity.
METHODS: Open-label, randomized, crossover study enrolling 54 patients with nocturnal GERD symptoms comparing IR-OME, lansoprazole and esomeprazole at steady state for nocturnal acid breakthrough (NAB), percentage of time with gastric pH > 4 and median gastric pH.
RESULTS: Onset of nocturnal acid control with IR-OME was rapid. During the first half of the night, percentage of time with gastric pH > 4 and median gastric pH were significantly higher after IR-OME compared to esomeprazole or lansoprazole (P < 0.001, both comparisons). Over the 8-h night-time period, acid control with IR-OME was significantly better than lansoprazole (P < 0.001), and comparable to esomeprazole. IR-OME reduced NAB compared with esomeprazole and lansoprazole (61% vs. 92% and 92%; P < 0.001, both comparisons).
CONCLUSIONS: Bedtime IR-OME provided more rapid control of night-time gastric pH and decreased NAB compared with esomeprazole and lansoprazole. Nocturnal acid control with IR-OME was superior to lansoprazole and comparable to esomeprazole. Bedtime dosing with IR-OME may be effective for patients with night-time heartburn.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17229243     DOI: 10.1111/j.1365-2036.2006.03191.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  20 in total

1.  Nocturnal acid breakthrough on proton pump inhibitor therapy: to treat or not to treat.

Authors:  Philip O Katz; Robert S Dudnick
Journal:  Curr Treat Options Gastroenterol       Date:  2008-02

2.  Chemoprevention of esophageal adenocarcinoma.

Authors:  Julian A Abrams
Journal:  Therap Adv Gastroenterol       Date:  2008-07       Impact factor: 4.409

3.  Night-time symptoms and their impact on sleep in patients with gastroesophageal reflux disease who have a partial response to proton pump inhibitors: a qualitative patient interview study.

Authors:  Anna Rydén; Mona Martin; Katarina Halling; Anna Niklasson
Journal:  Patient       Date:  2013       Impact factor: 3.883

Review 4.  The relationship between gastroesophageal reflux disease and sleep.

Authors:  Ronnie Fass
Journal:  Curr Gastroenterol Rep       Date:  2009-06

5.  Proton pump inhibitors in the management of GERD.

Authors:  Philip O Katz; Stacey Zavala
Journal:  J Gastrointest Surg       Date:  2009-09-23       Impact factor: 3.452

6.  Once-daily omeprazole/sodium bicarbonate heals severe refractory reflux esophagitis with morning or nighttime dosing.

Authors:  Diana M Orbelo; Felicity T Enders; Yvonne Romero; Dawn L Francis; Sami R Achem; Tushar S Dabade; Michael D Crowell; Debra M Geno; Ramona S DeJesus; Vikneswaran Namasivayam; Steven C Adamson; Amindra S Arora; Andrew J Majka; Jeffrey A Alexander; Joseph A Murray; Matthew Lohse; Nancy N Diehl; Mary Fredericksen; Kee Wook Jung; Margaret S Houston; Angela E O'Neil; David A Katzka
Journal:  Dig Dis Sci       Date:  2014-01-22       Impact factor: 3.199

Review 7.  Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease.

Authors:  Yu-Min Kung; Wen-Hung Hsu; Meng-Chieh Wu; Jiunn-Wei Wang; Chung-Jung Liu; Yu-Chung Su; Chao-Hung Kuo; Fu-Chen Kuo; Deng-Chyang Wu; Yao-Kuang Wang
Journal:  Dig Dis Sci       Date:  2017-11-06       Impact factor: 3.199

8.  Long lasting inhibitors of the gastric H,K-ATPase.

Authors:  Jai Moo Shin; George Sachs
Journal:  Expert Rev Clin Pharmacol       Date:  2009-09       Impact factor: 5.045

Review 9.  Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults.

Authors:  Kate McKeage; Stephanie K A Blick; Jamie D Croxtall; Katherine A Lyseng-Williamson; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Novel lansoprazole-loaded nanoparticles for the treatment of gastric acid secretion-related ulcers: in vitro and in vivo pharmacokinetic pharmacodynamic evaluation.

Authors:  Milind Alai; Wen Jen Lin
Journal:  AAPS J       Date:  2014-02-12       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.